Concepedia

Wee1 Inhibition

WEE1 Inhibition is a targeted molecular intervention strategy in cancer therapy that selectively suppresses the activity of the WEE1 kinase, a key regulator of the G2/M cell cycle checkpoint, thereby exacerbating genomic instability and inducing synthetic lethality in cancer cells with preexisting DNA damage response deficiencies.

443

Publications

31.4K

Citations

3.3K

Authors

804

Institutions

Publications per year

2017–2026

227

Parents

Publications

443

Negative regulation of mitosis by wee1+, a gene encoding a protein kinase homolog

Paul Russell, Paul Nurse · Cell · 1987 · 1K citations

, , +14

Inactivation of the p34 <sup> <i>cdc2</i> </sup> -Cyclin B Complex by the Human WEE1 Tyrosine Kinase

L L Parker, Helen Piwnica‐Worms · Science · 1992 · 714 citations

, , +15

mik1 and wee1 cooperate in the inhibitory tyrosine phosphorylation of cdc2

Karen Lundgren, Nancy C. Walworth, Robert Booher et al. · Cell · 1991 · 695 citations

, , +14

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

Hiroshi Hirai, Yoshikazu Iwasawa, Megumu Okada et al. · Molecular Cancer Therapeutics · 2009 · 550 citations

, , +17

Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15.

Clare H. McGowan, Paul Russell · The EMBO Journal · 1993 · 488 citations · Full text

, , +14

1–5 of 443

Authors

3.3K

  1. AM
    Amit M. Oza

    Princess Margaret Cancer Centre, Canada

    11 publications · 507 citations

    11

    h-index

  2. GM
    Ganesh Mugundu

    AstraZeneca (United States), United States

    10 publications · 341 citations

    10

    h-index

  3. MJ
    Mark J. O’Connor

    AstraZeneca (United Kingdom), United Kingdom

    9 publications · 812 citations

    9

    h-index

  4. TS
    Theodore S. Lawrence

    University of Michigan, United States

    8 publications · 943 citations

    8

    h-index

  5. SD
    Stuart D. Shumway

    Merck & Co., Inc., Rahway, NJ, USA (United States), United States

    8 publications · 1.8K citations

    8

    h-index

1–5 of 3.3K

Institutions

804

  1. The University of Texas MD Anderson Cancer Center

    Houston, United States

    22 h-index

    195 publications

    16.3K citations

  2. Harvard University

    Cambridge, United States

    18 h-index

    86 publications

    9K citations

  3. National Cancer Institute

    Bethesda, United States

    14 h-index

    85 publications

    7.2K citations

  4. Dana-Farber Cancer Institute

    Boston, United States

    13 h-index

    108 publications

    7.4K citations

  5. AstraZeneca (United Kingdom)

    Cambridge, United Kingdom

    13 h-index

    52 publications

    2.7K citations

  6. Huazhong University of Science and Technology

    Wuhan, China

    11 h-index

    119 publications

    4.5K citations

  7. National Institutes of Health

    Bethesda, United States

    11 h-index

    70 publications

    4K citations

  8. AstraZeneca (United States)

    Wilmington, United States

    11 h-index

    27 publications

    1.3K citations

1–8 of 804

Venues

  1. Clinical Cancer Research

    22 publications · 2.3K citations

    22

    h-index

  2. Molecular Cancer Therapeutics

    MCT · 15 publications · 1.9K citations

    15

    h-index

  3. Journal of Clinical Oncology

    19 publications · 1.7K citations

    14

    h-index

  4. Cancer Research

    14 publications · 751 citations

    13

    h-index

  5. Oncotarget

    12 publications · 513 citations

    12

    h-index

1–5